Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGIV-C 10% Rapid Infusion Trial in PID
NCT00220766Phase 3Completed
- Sponsor
- Grifols
- Start
- Aug 2002
- Primary completion
- Aug 2002
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, single-blind trial of intravenous human immunoglobulin in primary immunodeficiency (PI) (2 arms), sponsored by Grifols. Primary endpoint: Incidence and severity of all infusion related adverse events at 72 hours. Started Aug 2002; status: completed.
02
Drugs
intravenous human immunoglobulin
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT00220766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220766.